CRISPR & Cas Genes Market Size Worth $7.24 Billion By 2029 | CAGR: 18.2%

The global CRISPR & Cas genes market size is expected to reach USD 7.24 billion by 2029 according to a new study by Polaris Market Research. The report “CRISPR & Cas Genes Market Size, Share & Trends Analysis Report, By Product & Service (Product {Kits & Enzymes, Libraries, Design Tool, Antibodies, Others}, Service {Cell Line Engineering, gRNA Design, Microbial Gene Editing, DNA synthesis); By Application; By End Use; and By Region; Segment Forecasts, 2021 - 2029” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The advent of different anti-CRISPR proteins, which are predicted to increase the overall efficiency of the CRISPR technology is one of the major factors driving the industry growth. SpCas9-HF & eSpCas9 were two unique variants of the Cas9 protein created inside the lab to minimize off-target editing activities without using sgRNAs. During the projected period, North America is predicted to lead the entire genes market. The presence of essential companies, increased financing in biotechnology and genomes initiatives, and developed health systems are among the primary factors responsible for its huge market portion.

Have Questions? Request a sample or make an Inquiry before buying this report by clicking the following link: https://www.polarismarketresearch.com/industry-analysis/crispr-associated-cas-genes-market/request-for-sample

According to the Nature Journal May 2020 publication, the U.S. has already increased the COVID-19 testing while averaging about 250,000 COVID-19 tests per day. The rapid FDA approval of the test kits is expected to boost testing, reducing backlogs. Players in the market are focusing on adopting CRISPR & Cas genes-editing technology for engineering the blood stem cells and immune cells as a critical tool being deployed for enabling drug discovery while creating highly targeted anticancer drugs. Additionally, in May 2020, the U.S. Food and Drug Administration (FDA) approved the CRISPR-based diagnostic kit to test the SARS-CoV-2 COVID-19 coronavirus in the laboratory.

Companies operating in the global market are AstraZeneca plc. Beam Therapeutics, Add gene, Caribou Biosciences, Inc., CRISPR Therapeutics, Cellectis, Cibus, Danaher Corporation, eGenesis, Editas Medicine, Inc., F. Hoffmann-La Roche Ltd., Hera Bio Labs, GenScript, Horizon Discovery Group plc, Intellia Therapeutics, Inc., Inscripta, Inc., Intellia Therapeutics, Inc., Lonza, Merck KGaA, Mammoth Biosciences, OriGene Technologies, Inc., Recombine tics, Inc., PLANTeDIT, Synthego, Thermo Fisher Scientific, Inc., Takara Bio Inc., and Vertex Pharmaceuticals Incorporated.

Polaris Market Research has segmented the CRISPR & Cas Genes market report on the basis of product & service, application, end-use, and region:

CRISPR & Cas Genes Product & Service Outlook (Revenue - USD Million, 2017 - 2029)

• By Product
  • Kits & Enzymes
    • Vector-based Cas
    • DNA-free Cas
  • Libraries
  • Design Tool
  • Antibodies
  • Others
• By Service
  • Cell Line Engineering
  • gRNA Design
  • Microbial Gene Editing
  • DNA Synthesis

CRISPR & Cas Genes Application Outlook (Revenue - USD Million, 2017 - 2029)

• Biomedical
  • Genome Engineering
  • Disease Model Studies
  • Functional Genomics
  • Epigenetics
  • Others
• Agricultural

CRISPR & Cas Genes End-use Outlook (Revenue - USD Million, 2017 - 2029)

• Biotechnology & Pharmaceutical Companies
• Academics & Government Research Institutes
• Contract Research Organizations (CROs)

CRISPR & Cas Genes Regional Outlook (Revenue - USD Million, 2017 - 2029)

• North America
  • U.S.
  • Canada
• Europe
  • France
  • Germany
  • UK
  • Italy
  • Spain
  • Netherlands
  • Austria
• Asia Pacific
  • China
  • India
  • Japan
  • Malaysia
  • South Korea
  • Indonesia
• Central & South America
  • Mexico
  • Brazil
  • Argentina
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa